Roughly 22% of patients with G/GEJ adenocarcinoma exhibit over-expression of Her2 (21), a condition that accelerates tumor progression via pathways such as PI3K/Akt/mTOR and MAPK (22). Here, ERBB2 is linked to neoplasm.